Actively Recruiting
Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)
Led by Cuibai Wei，Clinical Professor · Updated on 2025-07-24
900
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
Sponsors
C
Cuibai Wei，Clinical Professor
Lead Sponsor
B
Beihang University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects more than 15% of the population over the age of 60 in China. About 15% patients with MCI could progress into dementia after two years and about one-third develop into dementia within five years, which will lead to suffering, as well as staggering economic and care burden. So, exploring the predicting biomarkers from MCI to dementia to identify and delay progression to dementia at an early stage is of great social and clinical significance. Some reports based on a single neural biomarker suggest that risk models can predict the conversion of MCI to dementia, but no widely recognized prediction models basing on multiple complex markers have been used in clinical practice. The objectives of this study are to outline the spectrum of MCI transforming into dementia through a 5-year prospective longitudinal cohort study; Secondly, screening biomarkers for MCI transmit to dementia are based on clinical symptoms, neuropsychology, neuroimaging, neuroelectrophysiology, and humoral markers tests data.
CONDITIONS
Official Title
Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged 50 to 85 years
- Meet the diagnostic criteria for mild cognitive impairment or dementia
- Neuropsychological scores: Mini-Mental State Examination (MMSE) 15-28 points, Clinical Dementia Rating (CDR) 1 point or less
- Patients and their families have been informed and signed informed consent
You will not qualify if you...
- Presence of other neurological diseases causing brain dysfunction such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, or normal intracranial pressure hydrocephalus
- Presence of systemic diseases causing cognitive impairment such as liver or kidney failure, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol or drug abuse
- Diseases preventing cooperation with cognitive examination
- Contraindications to magnetic resonance imaging
- Mental and neurodevelopmental delay
- Refusal to provide blood samples
- Refusal to sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xuan Wu Hospital of Capital Medical University
Beijing, Beijing Municipality, China, 100053
Actively Recruiting
Research Team
C
Cuibai Wei
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here